Format

Send to

Choose Destination
Int Urogynecol J. 2016 Mar;27(3):393-8. doi: 10.1007/s00192-015-2839-x. Epub 2015 Sep 12.

Effectiveness of botulinum toxin injection in the treatment of de novo OAB symptoms following midurethral sling surgery.

Author information

1
2nd Department of Gynaecology, Medical University of Lublin, ul. Jaczewskiego 8, 20-954, Lublin, Poland. pmiotla@wp.pl.
2
2nd Department of Gynaecology, Medical University of Lublin, ul. Jaczewskiego 8, 20-954, Lublin, Poland.
3
Department of Epidemiology and Biostatistics; Department of Urogynaecology, Imperial College London, London, UK.
4
Department of Paediatric Nursing, Medical University of Lublin, Lublin, Poland.

Abstract

INTRODUCTION AND HYPOTHESIS:

Intravesical onabotulinumtoxinA (Botox®) is effective for idiopathic overactive bladder (OAB) symptoms. Our primary objective was to compare the efficacy of onabotulinumtoxinA for women with de novo OAB after midurethral sling (MUS) surgery and women with idiopathic OAB.

METHODS:

Women enrolled in this prospective study had idiopathic (n = 53) or de novo (n = 49) OAB symptoms after MUS, with at least one episode of urgency urine incontinence per day. OnabotulinumtoxinA (100 U) was administered in 20 intradetrusor injections. Postvoid residual volumes were checked at 2, 4 and 12 weeks. Participants completed a 3-day bladder diary and the King's Health Questionnaire (KHQ) before and 12 weeks after treatment.

RESULTS:

After 12 weeks, 22 patients (41.5 %) in the idiopathic OAB and 19 patients (38.8 %) in the de novo OAB groups were completely dry. OnabotulinumtoxinA injections had a significant benefit within both groups (p <0.001) to decrease both the daily numbers of voids (-2.39 and -2.0) and incontinence episodes (-1.38 and -1.44), with no significant difference between groups. We observed an increase of mean voided volume of >90 ml in both groups. Urinary retention was observed in four patients.

CONCLUSIONS:

We observed similar improvement in OAB symptoms after intravesical onabotulinumtoxinA injections within both groups. The rates of retention and requirement for catheterization even for women with a prior MUS were acceptable. These observational data provide evidence that onabotulinumtoxinA can effectively treat patients with OAB following stress urinary incontinence surgery.

KEYWORDS:

Botulinum toxin; De novo OAB; Midurethral sling; Overactive bladder; Quality of life; Urgency incontinence

PMID:
26364180
PMCID:
PMC4766229
DOI:
10.1007/s00192-015-2839-x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center